蜂王浆
脂肪肝
安普克
酒精性肝病
肠道菌群
酒精性脂肪肝
脂肪酸
阿克曼西亚
医学
生物化学
脂肪性肝炎
化学
内科学
生物
丁酸盐
内分泌学
脂肪生成
药理学
肝损伤
疾病
肝病
作者
Lining Ren,Weiman Gao,Xinyu Ma,Haitao Zhang,Yuhang Xiao,Shijing Jiang,Guochen Liu,Aidong Sun
摘要
Royal jelly (RJ) and its bioactive compound, 10-hydroxy-2-decenoic acid (10-HDA), have been reported to possess hepatoprotective properties, yet their mechanisms against alcoholic fatty liver disease (AFLD) remain to be fully elucidated. This study integrated 16S rRNA sequencing, untargeted metabolomics, and molecular analyses to evaluate their therapeutic potential in an AFLD mouse model. Results indicated that RJ (200 mg/kg/day) and 10-HDA (100 mg/kg/day) alleviated alcohol-induced liver injury by reducing lipid accumulation, dyslipidemia, inflammation, and oxidative stress. Furthermore, these interventions modulated gut microbiota composition by decreasing the relative abundance of Pseudomonadota and Escherichia, while increasing taxa such as Akkermansia and Lactobacillus. Metabolomic profiling suggested the involvement of key pathways, including serotonergic synapse, bile secretion, and tryptophan metabolism. In the liver, RJ and 10-HDA treatment was associated with the activation of the AMPK pathway, which promotes fatty acid β-oxidation and suppresses lipogenesis. Notably, integrated correlation analyses indicated that the restoration of certain fecal metabolites correlated with hepatic AMPK activation. Collectively, RJ and 10-HDA may mitigate AFLD by modulating the gut-microbiota-metabolite axis and the AMPK signaling pathway, supporting their potential use as dietary supplements for liver health.
科研通智能强力驱动
Strongly Powered by AbleSci AI